Literature DB >> 29134641

Molecular Tumor Boards: Realizing Precision Oncology Therapy.

Maulik Patel1, Shumei M Kato2, Razelle Kurzrock2.   

Abstract

Technological advances in high-throughput next-generation sequencing (NGS) along with advances in computational processes have brought about the dawn of the genomic medicine era. NGS has enabled molecular characterization of malignancies, and facilitated the development and approval of gene- and immune-targeted therapies, both of which impact the mutanome. Clinical implementation of this technology, approval of novel targeted agents, and establishment of molecular tumor boards has enabled precision oncology to become a reality.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29134641      PMCID： PMC5760337          DOI： 10.1002/cpt.920

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  5 in total

1.  Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Authors:  Maria Schwaederle; Barbara A Parker; Richard B Schwab; Gregory A Daniels; David E Piccioni; Santosh Kesari; Teresa L Helsten; Lyudmila A Bazhenova; Julio Romero; Paul T Fanta; Scott M Lippman; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Authors:  Maria Schwaederle; Barbara A Parker; Richard B Schwab; Paul T Fanta; Sarah G Boles; Gregory A Daniels; Lyudmila A Bazhenova; Rupa Subramanian; Alice C Coutinho; Haydee Ojeda-Fournier; Brian Datnow; Nicholas J Webster; Scott M Lippman; Razelle Kurzrock
Journal:  Oncologist       Date:  2014-05-05

3.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Authors:  Himisha Beltran; Kenneth Eng; Juan Miguel Mosquera; Alexandros Sigaras; Alessandro Romanel; Hanna Rennert; Myriam Kossai; Chantal Pauli; Bishoy Faltas; Jacqueline Fontugne; Kyung Park; Jason Banfelder; Davide Prandi; Neel Madhukar; Tuo Zhang; Jessica Padilla; Noah Greco; Terra J McNary; Erick Herrscher; David Wilkes; Theresa Y MacDonald; Hui Xue; Vladimir Vacic; Anne-Katrin Emde; Dayna Oschwald; Adrian Y Tan; Zhengming Chen; Colin Collins; Martin E Gleave; Yuzhuo Wang; Dimple Chakravarty; Marc Schiffman; Robert Kim; Fabien Campagne; Brian D Robinson; David M Nanus; Scott T Tagawa; Jenny Z Xiang; Agata Smogorzewska; Francesca Demichelis; David S Rickman; Andrea Sboner; Olivier Elemento; Mark A Rubin
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

4.  Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

Authors:  Jennifer J Wheler; Filip Janku; Aung Naing; Yali Li; Bettzy Stephen; Ralph Zinner; Vivek Subbiah; Siqing Fu; Daniel Karp; Gerald S Falchook; Apostolia M Tsimberidou; Sarina Piha-Paul; Roosevelt Anderson; Danxia Ke; Vincent Miller; Roman Yelensky; J Jack Lee; David S Hong; Razelle Kurzrock
Journal:  Cancer Res       Date:  2016-05-18       Impact factor: 12.701

5.  Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

Authors:  Kim M Hirshfield; Denis Tolkunov; Hua Zhong; Siraj M Ali; Mark N Stein; Susan Murphy; Hetal Vig; Alexei Vazquez; John Glod; Rebecca A Moss; Vladimir Belyi; Chang S Chan; Suzie Chen; Lauri Goodell; David Foran; Roman Yelensky; Norma A Palma; James X Sun; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Howard Kaufman; Elizabeth Poplin; Janice Mehnert; Antoinette R Tan; Joseph R Bertino; Joseph Aisner; Robert S DiPaola; Lorna Rodriguez-Rodriguez; Shridar Ganesan
Journal:  Oncologist       Date:  2016-08-26
  5 in total
  11 in total

1.  Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.

Authors:  Lindsey M Charo; Ramez N Eskander; Jason Sicklick; Ki Hwan Kim; Hyo Jeong Lim; Ryosuke Okamura; Suzanna Lee; Rupa Subramanian; Richard Schwab; Rebecca Shatsky; Steven Plaxe; Shumei Kato; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2022-01

2.  Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations.

Authors:  Mina Nikanjam; Shumei Kato; Jacob J Adashek; Razelle Kurzrock
Journal:  Clin Oncol Case Rep       Date:  2021-12-15

3.  Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Authors:  Natalie Galanina; Razelle Kurzrock
Journal:  Cancer Biol Ther       Date:  2018-10-11       Impact factor: 4.742

Review 4.  Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.

Authors:  Shreya M Shah; Elena V Demidova; Randy W Lesh; Michael J Hall; Mary B Daly; Joshua E Meyer; Martin J Edelman; Sanjeevani Arora
Journal:  Cancer Treat Rev       Date:  2022-01-05       Impact factor: 13.608

5.  A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients.

Authors:  Michael J Pishvaian; Edik M Blais; R Joseph Bender; Shruti Rao; Simina M Boca; Vincent Chung; Andrew E Hendifar; Sam Mikhail; Davendra P S Sohal; Paula R Pohlmann; Kathleen N Moore; Kai He; Bradley J Monk; Robert L Coleman; Thomas J Herzog; David D Halverson; Patricia DeArbeloa; Emanuel F Petricoin; Subha Madhavan
Journal:  JAMIA Open       Date:  2019-10-07

6.  Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.

Authors:  Shumei Kato; Ryosuke Okamura; Jacob J Adashek; Noor Khalid; Suzanna Lee; Van Nguyen; Jason K Sicklick; Razelle Kurzrock
Journal:  JCI Insight       Date:  2021-01-11

7.  Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary.

Authors:  Shumei Kato; Caroline Weipert; Sophia Gumas; Ryosuke Okamura; Suzanna Lee; Jason K Sicklick; Jennifer Saam; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2021-11-03

8.  TP53-Deficient Angiosarcoma Expression Profiling in Rat Model.

Authors:  Urszula Smyczyńska; Damian Strzemecki; Anna M Czarnecka; Wojciech Fendler; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Magdalena Guzowska; Kamil Synoradzki; Łukasz Cheda; Zbigniew Rogulski; Paweł Grieb
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

9.  Implementing a clinical cutting-edge and decision-making activity: an ethnographic teamwork approach to a molecular tumorboard.

Authors:  Nathalie Bot; Mathias Waelli
Journal:  BMC Health Serv Res       Date:  2020-10-07       Impact factor: 2.655

10.  Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.

Authors:  Scott M Lippman; Razelle Kurzrock; Jason K Sicklick; Shumei Kato; Ryosuke Okamura; Hitendra Patel; Mina Nikanjam; Paul T Fanta; Michael E Hahn; Pradip De; Casey Williams; Jessica Guido; Benjamin M Solomon; Rana R McKay; Amy Krie; Sarah G Boles; Jeffrey S Ross; J Jack Lee; Brian Leyland-Jones
Journal:  Genome Med       Date:  2021-10-04       Impact factor: 11.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.